+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Cancer Antibody Drug Conjugate Market, Drug Sales, Price, & Clinical Trials Insight 2028

  • PDF Icon

    Report

  • 800 Pages
  • February 2022
  • Region: Global
  • Kuick Research
  • ID: 5550035
Description Jump to:

Global Cancer Antibody Drug Conjugate Market, Drug Sales, Price, & Clinical Trials Insight 2028 Report Highlights:

  • Global Cancer Antibody Drug Conjugate Market Opportunity > USD 25 Billion
  • Global Market Sales Trends & Market Forecast Till 2028
  • Clinical Insight On 18 Approved Cancer Antibody Drug Conjugates
  • Dosage, Price & Patent Insight On 18 Cancer Antibody Drug Conjugate
  • Quarterly & Yearly Drug Sales Insight & Forecast Till 2028
  • Clinical Insight On More Than 400 Cancer Drug Conjugates In Clinical Trials
  • Competitive Landscape

Global Cancer Antibody Drug Conjugate Market Analysis by County: 

US, Europe, Japan, China, South Korea, India, Australia, Taiwan, Canada

Global Cancer Antibody Drug Conjugate Market by Indication:

Breast Cancer, Lymphoma, Leukemia, Multiple Myeloma, Gastric Cancer, Lung Cancer

Antibody drug conjugates are the emerging class of cancer targeting drugs which are built by attaching a small cytotoxic agent to an antibody via linker. The antibody targets the specific antigen which is presence on the targeted cell and delivers the cytotoxic payload. The novel therapeutic class delivers the drug with very high specificity to the target cell, maximizing the efficacy and minimizing systemic exposure. The entrance of antibody drug conjugates for the management of cancer has shown to greatly revolutionize the paradigm of cancer therapy in short span of time. 

Presently, only 18 antibody drug conjugates have been approved by regulatory bodies for the management of various cancers including breast cancer, leukemia, lymphoma, multiple myeloma, gastrointestinal, and urothelial cancers. The breast cancer segment contributes to a majority of share in the market owing to the large number of product approved, increasing prevalence of breast cancer, and robust sales worldwide. However, it is estimated that during the forecast period lymphoma antibody drug conjugate segment will register high growth rates which is mainly attributed to large number of ongoing clinical trials, and new product launches during the forecast period. For instance, US FDA has recently granted permission to initiate phase-III clinical trial of Zilovertamab in relapsed/refractory mantle cell lymphoma. Zilovertamab developed by Oncternal Therapeutics is novel antibody drug conjugate targeting ROR1. 

The encouraging response of antibody drug conjugates in the management of cancer has further drive the research and development activities in this domain. The global market has diverse players which are involved in fierce competition. The research activities lead to new discoveries and treatment options, eventually adding value to the growth of the antibody drug conjugate market. The major key players in the market include Daiichi Sankyo, Roche, Gilead Sciences, ADC Therapeutics, AstraZenca, Seagen, Takeda Pharmaceuticals, and others. In addition to this, several small start-ups have also entered into license agreement with big pharmaceutical giants to maintain their position in the global market. These rising trends in the market points towards the positive future of antibody drug conjugates in cancer therapeutics. 

Apart from monotherapy, several ongoing clinical trials are also evaluating the role of antibody drug conjugates in combinational therapy to enhance the overall efficacy and to overcome drug resistance. For instance, Gilead Sciences has entered into collaboration with Merck to evaluate the combination of Trodelvy and Keytruda in first-line metastatic non-small cell lung cancer. Furthermore, researchers are also expanding the knowledge of antibody drug conjugate in targeting other diseases such as rheumatoid arthritis. AbbVie has developed ABBV-3373 which has shown significant improvement in patient with rheumatoid arthritis. The coming years will witness increased use of antibody drug conjugate in oncological as well as non-oncological conditions which will drive the growth of market. 

As per report findings, the global antibody drug conjugate market is expected to surpass US$ 25 Billion by 2028, thus registering high CAGR rates. Rising geriatric population associated with high cancer prevalence is one of the major factors which will influence the growth of market. In addition, other factors such as unmet need of targeted cancer therapy, increasing awareness about availability of antibody drug conjugates, rising investments by pharmaceutical companies, development of favorable reimbursement policies, and new product launches will also aid in the growth of market during the forecast period. 

The report provides comprehensive analysis on the currently available antibody drug conjugates in the market with their commercial information. The report also provides insights into ongoing clinical trials and major antibody drug conjugates in the development, which is expected to enter the market during the forecast period. Apart from this, competitive analysis and major trends ongoing in the market are also included in the report.

Table of Contents

1. Introduction to Antibody Drug Conjugates (ADCs)
1.1 Overview
1.2 Historical Development of ADCs
2. Evolution of Antibody Drug Conjugates
2.1 Advancements in ADCs
2.1.1 First Generation
2.1.2 Second-Generation
2.1.3 Third Generation
2.2 Components of ADCs
2.2.1 Monoclonal Antibodies (mAbs)
2.2.2 Linkers
2.2.3 Payloads
3. Antibody Drug Conjugates - Mechanism of Action
3.1 Antigen - Antibody Interaction
3.2 Release of Payload
3.3 Mechanism of Cytotoxicity
4. Need of Antibody Drug Conjugates
5. Role of ADCs in Cancer Management
5.1 Breast Cancer
5.2 Leukemia
5.3 Lymphoma
5.4 Other Cancers
6. Antibody Drug Conjugates - Availability, Dosage & Price Analysis
6.1 Mylotarg
6.2 Adectris
6.3 Kadcyla
6.4 Besponsa
6.5 Lumoxiti
6.6 Polivy
6.7 Enhertu
6.8 Padcev
6.9 Trodelvy
6.10 Blenrep
6.11 Zynlonta
6.12 Tivdak
6.13 Aidixi
6.14 Ujvira
6.15 Akalux
7. Antibody Drug Conjugate - Sales Insights & Forecast 2028
7.1 Adcetris
7.2 Padcev
7.3 Tivdak
7.4 Polivy
7.5 Kadcyla
7.6 Besponsa
7.7 Enhertu
7.8 Trodelvy
7.9 Zynlonta
7.10 Blenrep
8. Global Antibody Drug Conjugate Market
8.1 Current Market Scenario
8.2 Future Market Opportunity
9. Antibody Drug Conjugate Market Regional Analysis
9.1 US
9.2 Europe
9.3 Japan
9.4 China
9.5 South Korea
9.6 India
9.7 Australia
9.8 Taiwan
9.9 Canada
10. Antibody Drug Conjugate Market by Indication
10.1 Breast Cancer
10.2 Lymphoma
10.3 Leukemia
10.4 Multiple Myeloma
10.5 Gastric Cancer
10.6 Lung Cancer
11. Global Antibody Drug Conjugates Clinical Trials Insight 2022 - 2028
11.1 By Phase
11.2 By Indication
11.3 By Company
11.4 By Patient Segment
11.5 By Country
12. Global Cancer Antibody Drug Conjugates Clinical Pipeline By Company, Indication & Phase
12.1 Research
12.2 Preclinical
12.3 Clinical
12.4 Phase-0
12.5 Phase-I
12.6 Phase-I/II
12.7 Phase-II
12.8 Phase-II/III
12.9 Phase-III
12.10 Preregistration
12.11 Registered
13. Marketed Cancer Antibody Drug Conjugates Insight
14. Global Cancer an Antibody Drug Conjugates Market Dynamics
14.1 Favorable Parameters
14.2 Challenges for Antibody Drug Conjugates Market
15. Antibody Drug Conjugates Market - Future Outlook
16. Competitive Landscape
16.1 AstraZeneca plc
16.2 Genentech
16.3 Roche
16.4 Takeda Pharmaceuticals
16.5 Pfizer
16.6 Oxford BioTherapeutics
16.7 Heidelberg Pharma
16.8 Synthon
16.9 Mersana Therapeutics
16.10 Progenics Pharmaceuticals
16.11 Astellas Pharma
16.12 Bristol Mayer Squibb
16.13 Seattle Genetics
16.14 Immunogen
16.15 Celldex Therapeutics
List of Figures
Figure 1-1: Historical Development of Antibody-Drug Conjugate
Figure 1-2: Approval History of Commercially Available Antibody-Drug Conjugates
Figure 2-1: Classification of Antibody-Drug Conjugates
Figure 2-2: Components of Antibody-Drug Conjugates
Figure 2-3: Antigen Expression Analyzing Techniques used in Development of ADCs
Figure 2-4: Isotypes of Monoclonal Antibodies used in ADC Development
Figure 2-5: Classification of Linkers
Figure 2-6: Types of Cleavable Linkers
Figure 2-7: Non-Cleavable Linker Used in ADCs Development
Figure 2-8: Cytotoxic drugs used in Antibody Drug Conjugates
Figure 3-1: General Mechanism of Antibody Drug Conjugates against Cancer
Figure 3-2: ADCs - Antigen-Antibody Interaction in Normal & Cancerous Cells
Figure 3-3: Releasing Mechanism of Payloads
Figure 3-4: Mechanism of Cytotoxicity via Alkylating Agents
Figure 3-5: Mechanism of Toxicity via Tubulin Inhibitors
Figure 4-1: Therapeutic Index - Antibody Drug Conjugate vs. Cytotoxic Drug
Figure 6-1: Mylotarg - FDA Approval, Withdrawal & Re-Approval Year
Figure 6-2: Mylotarg - Approval Year by Region
Figure 6-3: UK - Cost of Supply of Mylotarg 5mg Intravenous Powder (GBP/US$), January'2022
Figure 6-4: Mylotarg - Cost of Supply of Vial for Injection by Region (US$), January'2022
Figure 6-5: Mylotarg - Number of Induction Cycle & Consolidation Cycle Required for Treatment of Newly Diagnosed De Novo CD33-positive AML
Figure 6-6: Mylotarg - Cost of Induction Cycle, Consolidation Cycles & Full Treatment Cost of Newly Diagnosed De Novo CD33-positive AML (US$), January'2022
Figure 6-7: Mylotarg - Recommended Number of Induction & Continuation Cycle for Treatment of Newly Diagnosed CD-33 Positive AML
Figure 6-8: Mylotarg - Length of Induction & Continuation Cycle for Treatment of Newly Diagnosed CD-33 positive AML (Days)
Figure 6-9: Mylotarg - Recommended Dose of Initial Dose & Continuation Dose for Treatment of Newly Diagnosed CD-33 positive AML (mg/m2)
Figure 6-10: Mylotarg - Cost of Induction Phase & Continuation Phase & Full Treatment Cost of CD-33 positive AML (US$), Janauary'2022
Figure 6-11: Mylotarg - Cost of Single Dose & Full Treatment Cost of Relapsed & Refractory CD33 Positive AML, January'2022
Figure 6-12: US - Adcetris Oprhan Drug Designation Approval Year by Indication
Figure 6-13: US - Adcetris FDA Approval Year by Indication
Figure 6-14: Adcetris - Approval Year by Region
Figure 6-15: Japan - Adcetris FDA Approval Year by Indication
Figure 6-16: Adcetris - Patent Expiration by Region
Figure 6-17: UK - Cost of Supply of Adcetris 50mg Intravenous Powder (GBP/US$), January'2022
Figure 6-18: Adcetris - Cost of Supply of Vial for Injection by Region (US$), January'2022
Figure 6-19: Adcetris - Duration of Single Treatment Cycle & Full Treatment of Stage III and IV Classical Hodgkin Lymphoma (Weeks)
Figure 6-20: Adcetris - Maximum Cost of Single Treatment Cycle & Full Treatment of Stage III and IV Classical Hodgkin Lymphoma (US$), January'2022
Figure 6-21: Adcetris - Duration of Single Treatment Cycle & Full Treatment of Classical Hodgkin Lymphoma (Weeks)
Figure 6-22: Adcetris - Maximum Cost of Single Treatment Cycle & Full Treatment of Classical Hodgkin Lymphoma (US$), January'2022
Figure 6-23: Adcetris - Maximum Cost of Single Treatment Cycle & Full Treatment of Previously Untreated Systemic ALCL or Other CD30 T-Cell Lymphomas (US$), January'2022
Figure 6-24: Adcetris - Duration of Single Treatment Cycle & Full Treatment of Relapsed Primary Cutaneous ALCL or CD30-Expressing MF (Weeks)
Figure 6-25: Adcetris - Maximum Cost of Single Treatment Cycle & Full Treatment of Relapsed Primary Cutaneous ALCL or CD30-Expressing MF (US$), January'2022
Figure 6-26: US - Kadcyla FDA Approval Year by Indication
Figure 6-27: Kadcyla - Approval Year by Region
Figure 6-28: US - Kadcyla FDA Approval & Patent Expiration Year
Figure 6-29: US - Price for Single Unit of Kadcyla 100mg & 160mg Intravenous Powder for Injection (US$), January'2022
Figure 6-30: UK - Price for Single Unit of Kadcyla 100mg & 160mg Intravenous Powder for Injection (GBP/US$), January'2022
Figure 6-31: Kadcyla - Duration of Single Treatment Cycle & Full Treatment of Early Stage HER2+ Breast Cancer (Weeks)
Figure 6-32: Kadcyla - Average Cost of Single Treatment Cycle & Full Treatment of Early Stage HER2 Breast Cancer in Human with Average Weight (US$), January'2022
Figure 6-33: Kadcyla - Recommended Dose After 1st & 2nd Dose Reduction (mg/m2)
Figure 6-34: Besponsa - Approval Year by Region
Figure 6-35: UK - Cost of Supply of Besponsa 0.9mg Intravenous Powder (GBP/US$), January'2022
Figure 636: Besponsa - Cost of Supply of Vial for Injection by Region (US$), January'2022
Figure 6-37: Besponsa - Duration of Initial Treatment Cycle & Subsequent Cycles (Days)
Figure 6-38; Besponsa - Recommended Dose for 1st, 8th & 15th Day of Initial Treatment Cycle (mg/m2)
Figure 6-39: Besponsa - Cost of Single Unit & Full Cost of Initial Treatment Cycle (US$), January'2022
Figure 6-40: Besponsa - Cost of Single Unit & Full Cost of Subsequent Treatment Cycle in Patient with CR (US$), January'2022
Figure 6-41: Besponsa - Duration of Treatment of ALL - After & Without HSCT (Weeks)
Figure 6-42: Lumoxiti - Year of Orphan Designation, FDA Approval & Patent Expiration
Figure 6-43: Lumoxiti - Duration of Single Treatment Cycle & Full Treatment (Weeks)
Figure 6-44: Lumoxitin - Cost of Single Dose, Single Treatment Cycle & Full Treatment of Hairy Cell Leukemia (US$), January'2022
Figure 6-45: Polivy - Orphan Drug Designation Approval Year by Region
Figure 6-46: US - Polivy Orphan Drug Designation Approval & Exclusivity Year
Figure 6-47: Polivy - Approval Year by Region
Figure 6-48: US - Price for Single Unit of Polivy 30mg & 140mg Intravenous Powder for Injection (US$), January'2022
Figure 6-49: UK - Price for Single Unit of Polivy 30mg & 140mg Intravenous Powder for Injection (GBP/US$), January'2022
Figure 6-50: Polivy - Duration of Single Treatment Cycle & Full Treatment (Weeks)
Figure 6-51: Polivy - Cost of Single Dose, Single Treatment Cycle & Full Treatment of Hairy Cell Leukemia (US$), January'2022
Figure 6-52: US - Enhertu Orphan Drug Designation Approval & Exclusivity Year
Figure 6-53: Enhertu - Approval Year by Region
Figure 6-54: US - Polivy FDA Approval Year by Indication
Figure 6-55: UK - Cost of Supply of Enhertu 100mg Intravenous Powder (GBP/US$), January'2022
Figure 6-56: Besponsa - Cost of Supply of Vial for Injection by Region (US$), January'2022
Figure 6-57: Enhertu - Recommended Dose by Cancer Type (mg/Kg)
Figure 6-58: Enhertu - Average Cost of Single Treatment Cycle & Annual Treatment Cost (US$), January'2022
Figure 6-59: Enhertu - Recommended Dose & Dose after Reduction for Breast Cancer (mg/Kg)
Figure 6-60: Enhertu - Recommended Dose & Dose after Reduction for Gastric Cancer (mg/Kg)
Figure 6-61: Padcev - Approval Year by Region
Figure 6-62: US - Padcev FDA Approval & Patent Expiration Year
Figure 6-63: US - Price for Padcev 20mg & 30mg Intravenous Powder for Injection (US$), January'2022
Figure 6-64: Padcev - Average Cost of Single Dose, Single Treatment Cycle & Full Treatment (US$), January'2022
Figure 6-65: Padcev - Recommended Minimum Dose & Dose after Reduction for Urothelial Cancer (mg/Kg)
Figure 6-66: Padcev - Recommended Maximum Dose & Dose after Reduction for Urothelial Cancer (mg)
Figure 6-67: US - Trodelvy FDA Approval by Indication
Figure 6-68: Trodelvy - Approval Year by Region
Figure 6-69: Trodelvy - Patent Expiration by Region
Figure 6-70: Trodelvy - Average Cost of Single Dose, Single Treatment Cycle & Annual Treatment Cost (US$), January'2022
Figure 6-71: Trodelvy - Recommended Dose & Dose after Reduction (mg/Kg)
Figure 6-72: US - Blenrep FDA Orphan Drug Designation & Approval Year
Figure 6-73: US - Blenrep FDA Orphan Drug Designation Approval & Patent Exclusivity Year
Figure 6-74: Europe - Blenrep FDA Orphan Drug Designation & Approval Year
Figure 6-75: Europe - Cost of Supply of Blenrep 100mg Intravenous Powder (Euro/US$), January'2022
Figure 6-76: Blenrep - Cost of Supply of Vial for Injection by Region (US$), January'2022
Figure 6-77: Blenrep - Average Cost of Single Treatment Cycle & Annual Treatment Cost (US$), January'2022
Figure 6-78: Blenrep - Recommended Dose & Dose after Reduction (mg/Kg)
Figure 6-79: US - Zynlonta FDA Orphan Drug Designation Approval & Patent Exclusivity Year
Figure 6-80: US - Zynlonta Orphan Drug Designation & FDA Approval Year
Figure 6-81: Zynlonta - Orphan Drug Designation by Region
Figure 6-82: Zynlonta - Average Cost of Single Treatment Cycle & Annual Treatment Cost (US$), January'2022
Figure 6-83: Zynlonta - Recommended Dose for Initial & Subsequent Cycles (mg/kg)
Figure 6-84: Tivdak - Average Cost of Single Treatment Cycle & Annual Treatment Cost (US$), January'2022
Figure 6-85: Tivdak - Maximum Cost of Single Treatment Cycle & Annual Treatment Cost (US$), January'2022
Figure 6-86: Tivdak - Recommended Dose & Dose after Reduction (mg/Kg)
Figure 6-87: Aidixi - China Approval Year & FDA Breakthrough Therapy Designation Year
Figure 6-88: India - Price for Single Unit of Ujvira 100mg & 160mg Intravenous Powder for Injection (INR/US$), January'2022
Figure 6-89: India - Price for Single Unit of Branded & Biosimilar Trastuzumab Emtansine 100mg Powder for Injection (INR/US$), January'2022
Figure 6-90: Ujvira - Duration of Single Treatment Cycle & Full Treatment of Early Stage HER2+ Breast Cancer (Weeks)
Figure 6-91: Ujvira - Recommended Dose After 1st & 2nd Dose Reduction (mg/m2)
Figure 6-92: Akalux - Sakigake Designation & PMDA Approval Year
Figure 7-1: Global - Adcetris Annual Sales (US$ Million), 2018 - 2021
Figure 7-2: Global - Adcetris Quarterly Sales (US$ Million), 2021
Figure 7-3: Global - Adcetris Quarterly Sales (US$ Million), 2020
Figure 7-4: Global - Adcetris Annual Sales (US$ Million), 2022 - 2028
Figure 7-5: Global - Padecv Annual Sales (US$ Million), 2019 - 2021
Figure 7-6: Global - Padcev Quarterly Sales (US$ Million), 2021
Figure 7-7: Global - Padcev Quarterly Sales (US$ Million), 2020
Figure 7-8: Global - Padcev Annual Sales (US$ Million), 2022 - 2028
Figure 7-9: Global - Tivdak Annual Sales (US$ Million), 2021 - 2028
Figure 7-10: Global - Polivy Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 7-11: Global - Polivy Quarterly Sales Value (US$/CHF Million), 2021
Figure 7-12: US - Polivy Quarterly Sales Value (US$/CHF Million), 2021
Figure 7-13: Europe - Polivy Quarterly Sales Value (US$/CHF Million), 2021
Figure 7-14: Japan - Polivy Quarterly Sales Value (US$/CHF Million), Q2-Q4’2021
Figure 7-15: ROW - Polivy Quarterly Sales Value (US$/CHF Million), 2021
Figure 7-16: Polivy - Quarterly Sales Value by Region (US$/CHF Million), 2021
Figure 7-17: Polivy - Quarterly Sales Value by Region (%), 2021
Figure 7-18: Global - Polivy Quarterly Sales Value (US$/CHF Million), 2020
Figure 7-19: US - Polivy Quarterly Sales Value (US$/CHF Million), 2020
Figure 7-20: Europe - Polivy Quarterly Sales Value (US$/CHF Million), 2020
Figure 7-21: Polivy - Annual Sales Value by Region (US$/CHF Million), 2020
Figure 7-22: Polivy - Annual Sales Value by Region (%), 2020
Figure 7-23: Polivy - Quarterly Sales Value (US$/CHF Million), Q2-Q4'2019
Figure 7-24: Global - Polivy Annual Sales (US$ Million), 2022 - 2028
Figure 7-25: US - Polivy Annual Sales (US$ Million), 2022 - 2028
Figure 7-26: Europe - Polivy Annual Sales (US$ Million), 2022 - 2028
Figure 7-27: Japan - Polivy Annual Sales (US$ Million), 2022 - 2028
Figure 7-28: ROW - Polivy Annual Sales (US$ Million), 2022 - 2028
Figure 7-29: Global - Kadcyla Annual Sales Value (US$/CHF Million), 2018 - 2021
Figure 7-30: Global - Kadcyla Quarterly Sales Value (US$/CHF Million), 2021
Figure 7-31: US - Kadcyla Quarterly Sales Value (US$/CHF Million), 2021
Figure 7-32: Europe - Kadcyla Quarterly Sales Value (US$/CHF Million), 2021
Figure 7-33: Japan - Kadcyla Quarterly Sales Value (US$/CHF Million), 2021
Figure 7-34: ROW - Kadcyla Quarterly Sales Value (US$/CHF Million), 2021
Figure 7-35: Kadcyla - Quarterly Sales Value by Region (US$/CHF Million), 2021
Figure 7-36: Kadcyla - Quarterly Sales Value by Region (%),2021
Figure 7-37: Global - Kadcyla Quarterly Sales Value (US$/CHF Million), 2020
Figure 7-38: US - Kadcyla Quarterly Sales Value (US$/CHF Million), 2020
Figure 7-39: Europe - Kadcyla Quarterly Sales Value (US$/CHF Million), 2020
Figure 7-40: Japan - Kadcyla Quarterly Sales Value (US$/CHF Million), 2020
Figure 7-41: ROW - Kadcyla Quarterly Sales Value (US$/CHF Million), 2020
Figure 7-42: Kadcyla - Annual Sales Value by Region (US$/CHF Million), 2020
Figure 7-43: Kadcyla - Annual Sales Value by Region (%). 2020
Figure 7-44: Global - Kadcyla Quarterly Sales Value (US$/CHF Million), 2019
Figure 7-45: US - Kadcyla Quarterly Sales Value (US$/CHF Million), 2019
Figure 7-46: Europe - Kadcyla Quarterly Sales Value (US$/CHF Million), 2019
Figure 7-47: Japan - Kadcyla Quarterly Sales Value (US$/CHF Million), 2019
Figure 7-48: ROW - Kadcyla Quarterly Sales Value (US$/CHF Million), 2019
Figure 7-49: Kadcyla - Annual Sales Value by Region (US$/CHF Million), 2019
Figure 7-50: Global - Kadcyla Annual Sales (US$ Million), 2022 - 2028
Figure 7-51: US - Kadcyla Annual Sales (US$ Million), 2022 - 2028
Figure 7-52: Europe - Kadcyla Annual Sales (US$ Million), 2022 - 2028
Figure 7-53: Japan - Kadcyla Annual Sales (US$ Million), 2022 - 2028
Figure 7-54: ROW - Kadcyla Annual Sales (US$ Million), 2022 - 2028
Figure 7-55: Global - Besponsa Annual Sales (US$ Million), 2020 & 2021
Figure 7-56: Global - Besponsa Quarterly Sales (US$ Million), 2020 & 2021
Figure 7-57: US - Besponsa Quarterly Sales (US$ Million), 2020 & 2021
Figure 7-58: Europe - Besponsa Quarterly Sales (US$ Million), 2020 & 2021
Figure 7-59: ROW - Besponsa Quarterly Sales (US$ Million), 2020 & 2021
Figure 7-60: Besponsa - Annual Sales by Region (US$ Million), 2020 & 2021
Figure 7-61: Besponsa - Quarterly Sales by Region (%), 2020
Figure 7-62: Besponsa - Quarterly Sales by Region (%), 2021
Figure 7-63: Global - Besponsa Annual Sales (US$ Million), 2022 - 2028
Figure 7-64: US - Besponsa Annual Sales (US$ Million), 2022 - 2028
Figure 7-65: Europe - Besponsa Annual Sales (US$ Million), 2022 - 2028
Figure 7-66: ROW - Besponsa Annual Sales (US$ Million), 2022 - 2028
Figure 7-67: Global - Enhertu Annual Sales (US$ Million), 2020 & 2021
Figure 7-68: Global - Enhertu Quarterly Sales (US$ Million), 2021
Figure 7-69: Global - Enhertu Quarterly Sales (US$ Million), 2020
Figure 7-70: Global - Enhertu Annual Sales (US$ Million), 2022 - 2028
Figure 7-71: Global - Trodelvy Annual Sales (US$ Million), 2020 & 2021
Figure 7-72: Global - Trodelvy Quarterly Sales (US$ Million), 2021
Figure 7-73: Trodelvy - Annual Sales by Region (US$ Million), 2021
Figure 7-74: Trodelvy - Annual Sales by Region (%), 2021
Figure 7-75: Global - Trodelvy Annual Sales (US$ Million), 2022 - 2028
Figure 7-76: Global - Zynlonta Quarterly Sales (US$ Million), Q2 & Q3'2021
Figure 7-77: Global - Zynlonta Annual Sales (US$ Million), 2022 - 2028
Figure 7-78: Global - Blenrep Annual Sales (US$ Million), 2020 & 2021
Figure 7-79: Global - Blenrep Quarterly Sales (Euro/US$ Million), 2021
Figure 7-80: US - Blenrep Quarterly Sales (Euro/US$ Million), 2021
Figure 7-81: Europe - Blenrep Quarterly Sales (Euro/US$ Million), 2021
Figure 7-82: Blenrep - Quarterly Sales by Region (Euro/US$ Million), 2021
Figure 7-83: Blenrep - Quarterly Sales by Region (%), 2021
Figure 7-84: Global - Blenrep Quarterly Sales (Euro/US$ Million), 2020
Figure 7-85: Global - Blenrep Annual Sales (US$ Million), 2022 - 2028
Figure 7-86: US - Blenrep Annual Sales (US$ Million), 2022 - 2028
Figure 7-87: Europe - Blenrep Annual Sales (US$ Million), 2022 - 2028
Figure 7-88: ROW - Blenrep Annual Sales (US$ Million), 2022 - 2028
Figure 8-1: Global - Antibody Drug Conjugate Market (US$ Billion), 2020 & 2021
Figure 8-2: Antibody Drug Conjugate Market Size by Region (US$ Billion), 2021
Figure 8-3: Antibody Drug Conjugate Market Size by Region (%), 2021
Figure 8-4: Global - Antibody Drug Conjugate Market Size (US$ Billion), 2022 - 2028
Figure 9-1: US - Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 9-2: US vs. ROW - Antibody Drug Conjugate Market Size (US$ Billion), 2021
Figure 9-3: US vs. ROW - Antibody Drug Conjugate Market Size (%), 2021
Figure 9-4: US - Antibody Drug Conjugate Market Size (US$ Billion), 2022 - 2028
Figure 9-5: Europe - Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 9-6: Europe vs. ROW - Antibody Drug Conjugate Market Size (US$ Billion), 2021
Figure 9-7: Europe vs. ROW - Antibody Drug Conjugate Market Size (%), 2021
Figure 9-8: Europe - Antibody Drug Conjugate Market Size (US$ Billion), 2022 - 2028
Figure 9-9: Japan - Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 9-10: Japan vs. ROW - Antibody Drug Conjugate Market Size (US$ Billion), 2021
Figure 9-11: Japan vs. ROW - Antibody Drug Conjugate Market Size (%), 2021
Figure 9-12: Japan - Antibody Drug Conjugate Market Size (US$ Billion), 2022 - 2028
Figure 9-13: China - Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 9-14: China vs. ROW - Antibody Drug Conjugate Market Size (US$ Billion), 2021
Figure 9-15: China vs. ROW - Antibody Drug Conjugate Market Size (%), 2021
Figure 9-16: China - Antibody Drug Conjugate Market Size (US$ Billion), 2022 - 2028
Figure 9-17: South Korea - Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 9-18: South Korea vs. ROW - Antibody Drug Conjugate Market (US$ Billion), 2021
Figure 9-19: South Korea vs. ROW - Antibody Drug Conjugate Market (%), 2021
Figure 9-20: South Korea - Antibody Drug Conjugate Market Size (US$ Billion), 2022 - 2028
Figure 9-21: India - Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 9-22: India - Antibody Drug Conjugate Market Size (US$ Million), 2021 - 2028
Figure 9-23: Australia - Cancer Incidences & Deaths, 2020 & 2025
Figure 9-24: Australia - Antibody Drug Conjugate Market Size (US$ Million), 2021 - 2028
Figure 9-25: Taiwan - Antibody Drug Conjugate Market Size (US$ Million), 2021 - 2028
Figure 9-26: Canada - Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 9-27: Canada vs. ROW - Antibody Drug Conjugate Market Size (US$ Billion), 2021
Figure 9-28: Canada vs. ROW - Antibody Drug Conjugate Market Size (%), 2021
Figure 9-29: Canada - Antibody Drug Conjugate Market Size (US$ Billion), 2022 - 2028
Figure 10-1: Global - Breast Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 10-2: Global - Antibody Drug Conjugate Market Size by Indication (US$ Billion), 2021
Figure 10-3: Global - Antibody Drug Conjugate Market by Indication (%), 2021
Figure 10-4: Global - Breast Cancer Antibody Drug Conjugate Market Size (US$ Billion), 2022 - 2028
Figure 10-5: Global - Hodgkin & Non-Hodgkin Lymphoma Incidences (Million), 2020 & 2025
Figure 10-6: Global - Antibody Drug Conjugate Market Size by Indication (US$ Billion), 2021
Figure 10-7: Global - Antibody Drug Conjugate Market by Indication (%), 2021
Figure 10-8: Global - Lymphoma Antibody Drug Conjugate Market Size (US$ Billion), 2022 - 2028
Figure 10-9: Global - Leukemia Incidences & Deaths, 2020 & 2025
Figure 10-10: Global - Leukemia Antibody Drug Conjugate Market Size (US$ Billion), 2021 - 2028
Figure 10-11: Global - Multiple Myeloma Incidences & Deaths, 2020 & 2025
Figure 10-12: Global - Multiple Myeloma Antibody Drug Conjugate Market Size (US$ Billion), 2021 - 2028
Figure 10-13: Global - Gastric Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 10-14: Global - Gastric Cancer Antibody Drug Conjugate Market Size (US$ Billion), 2021 - 2028
Figure 10-15: Global - Lung Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 10-16: Global - Lung Cancer Antibody Drug Conjugate Market Size (US$ Billion), 2023 - 2028
Figure 11-1: Global - Antibody Drug Conjugate Clinical Pipeline by Phase (Numbers), 2022 till 2028
Figure 11-2: Global - Antibody Drug Conjugate Clinical Pipeline by Indication, 2022 till 2028
Figure 11-3: Global - Antibody Drug Conjugate Clinical Pipeline by Company, 2022 till 2028
Figure 11-4: Global - Antibody Drug Conjugate Clinical Pipeline by Patient Segment, 2022 till 2028
Figure 11-5: Global - Antibody Drug Conjugate Clinical Pipeline by Country, 2022 till 2028
Figure 14-1: Antibody Drug Conjugates Market Drivers
Figure 14-2: Challenges for Antibody Drug Conjugates Market

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AstraZeneca plc
  • Genentech
  • Roche
  • Takeda Pharmaceuticals
  • Pfizer
  • Oxford BioTherapeutics
  • Heidelberg Pharma
  • Synthon
  • Mersana Therapeutics
  • Progenics Pharmaceuticals
  • Astellas Pharma
  • Bristol Mayer Squibb
  • Seattle Genetics
  • Immunogen
  • Celldex Therapeutics

Related Topics

Related Reports

Global Cancer Antibody Drug Conjugates Market Size, Drug Sales, Drug Dosage, Price, & Clinical Trials Outlook 2029 - Product Image

Global Cancer Antibody Drug Conjugates Market Size, Drug Sales, Drug Dosage, Price, & Clinical Trials Outlook 2029

  • Report
  • 900 Pages
  • Global
From
Antibody Drug Conjugate Market (7th Edition): Distribution by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens And Key Geographical Regions (North America, Europe, and Asia-Pacific): Industry Trends and Global Forecasts, 2023-2035 - Product Image

Antibody Drug Conjugate Market (7th Edition): Distribution by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens And Key Geographical Regions (North America, Europe, and Asia-Pacific): Industry Trends and Global Forecasts, 2023-2035

  • Report
  • 716 Pages
  • Global
From
Global Antibody Drug Conjugates (ADC) Market by Product (Kadcyla, Enhertu, Padcev, Polivy), Linker Type (Cleavable, Non-Cleavable), Payload Type (Calicheamicin, MMAE), Target (HER2, CD30, CD22), Disease, and Region - Forecast to 2028 - Product Image

Global Antibody Drug Conjugates (ADC) Market by Product (Kadcyla, Enhertu, Padcev, Polivy), Linker Type (Cleavable, Non-Cleavable), Payload Type (Calicheamicin, MMAE), Target (HER2, CD30, CD22), Disease, and Region - Forecast to 2028

  • Report
  • 273 Pages
  • Global
From
Antibody Drug Conjugates Market Size and Forecasts 2020-2030, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Technology, Application, Distribution Channel, and Geography - Product Image

Antibody Drug Conjugates Market Size and Forecasts 2020-2030, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Technology, Application, Distribution Channel, and Geography

  • Report
  • 178 Pages
  • Global
From
Global Antibody Drug Conjugate Market by Mechanism of Action (CD30 Antibodies, ErbB2 Antibodies), Drugs (Adcetris, Blenrep, Enhertu), Technology, Indication, End User - Forecast 2023-2030 - Product Image

Global Antibody Drug Conjugate Market by Mechanism of Action (CD30 Antibodies, ErbB2 Antibodies), Drugs (Adcetris, Blenrep, Enhertu), Technology, Indication, End User - Forecast 2023-2030

  • Report
  • 181 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.